prikaz prve stranice dokumenta Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty
  Download
PDF 3.37 MB
Scientific paper - Original scientific paper
Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty
International Orthopaedics, 36 (2012), 4; 703-709. https://doi.org/10.1007/s00264-011-1367-7
Buljan, Melita; Nemet, Damir; Golubić-Ćepulić, Branka; Bićanić, Goran; Tripković, Branko; Delimar, Domagoj

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Buljan, M., Nemet, D., Golubić Ćepulić, B., Bićanić, G., Tripković, B. & Delimar, D. (2012). Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. International Orthopaedics, 36. (4), 703-709. doi: 10.1007/s00264-011-1367-7

Buljan, Melita, et al. "Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty." International Orthopaedics, vol. 36, no. 4, 2012, pp. 703-709. https://doi.org/10.1007/s00264-011-1367-7

Buljan, Melita, Damir Nemet, Branka Golubić Ćepulić, Goran Bićanić, Branko Tripković and Domagoj Delimar. "Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty." International Orthopaedics 36, no. 4 (2012): 703-709. https://doi.org/10.1007/s00264-011-1367-7

Buljan, M., et al. (2012) 'Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty', International Orthopaedics, 36(4), pp. 703-709. doi: 10.1007/s00264-011-1367-7

Buljan M, Nemet D, Golubić Ćepulić B, Bićanić G, Tripković B, Delimar D. Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. International Orthopaedics [Internet]. 2012 April [cited 2024 April 29];36(4):703-709. doi: 10.1007/s00264-011-1367-7

M. Buljan, D. Nemet, B. Golubić Ćepulić, G. Bićanić, B. Tripković and D. Delimar, "Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty", International Orthopaedics, vol. 36, no. 4, pp. 703-709, April 2012. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:792126. [Accessed: 29 April 2024]

Metadata
Title (english)Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty
AuthorMelita Buljan
AuthorDamir Nemet
AuthorBranka Golubić-Ćepulić
AuthorGoran Bićanić
AuthorBranko Tripković
AuthorDomagoj Delimar
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
PURPOSE: Our aim was to evaluate the effectiveness of two different dosing regimens of human recombinant erythropoietin (rHu-EPO) for preoperative autologous blood collection in patients undergoing total hip arthroplasty (THA). ----- METHODS: Prospective randomised trials in which erythropoietin 15,000 IU was administered intravenously twice a week or 30,000 IU once a week (total 90,000 IU) combined with ferrous II sulphate (Ferro-Gradumet 2) orally and compared with Ferro-Gradumet 2 alone. ----- RESULTS: Although different dosing regimens of rHu-EPO administration during preoperative autologous blood donation have similar effects on the collection of two units of autologous blood, preoperative haemoglobin level and perioperative allogenic blood transfusion, a once weekly dose regimen of rHu-EPO was more convenient (although not statistically significantly) for patients. ----- CONCLUSION: We recommend the more practical and comfortable but yet highly effective therapeutic regimen with a single weekly intravenous administration of rHu-EPO for patients scheduled for THA.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleInternational Orthopaedics
Numberingvol. 36, no. 4, pp. 703-709
p-ISSN0341-2695
DOIhttps://doi.org/10.1007/s00264-011-1367-7
URN:NBNurn:nbn:hr:105:792126
Publication2012-04
Document URLhttps://doi.org/10.1007/s00264-011-1367-7
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-27 19:31:14